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Abstract
Background and objective Patients with anteromedial
arthritis who require a knee replacement could receive
either a unicompartmental knee replacement (UKR) or a
total knee replacement (TKR). This review has been
undertaken to identify economic evaluations comparing
UKR and TKR, evaluate the approaches that were taken in
the studies, assess the quality of reporting of these evalu-
ations, and consider what they can tell us about the relative
value for money of the procedures.
Methods A search of MEDLINE, EMBASE and the Centre
for Reviews and Dissemination National Health Service
Economic Evaluation Database was undertaken in January
2016 to identify relevant studies. Study characteristics were
described, the quality of reporting and methods assessed
using the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) checklist, and study find-
ings summarised.
Results Twelve studies satisfied the inclusion criteria. Five
were within-study analyses, while another was based on a
literature review. The remaining six studies were model-
based analyses. All studies were informed by observational
data. While methodological approaches varied, studies
generally had either limited follow-up, did not fully
account for baseline differences in patient characteristics or
relied on previous research that did not. The quality of
reporting was generally adequate across studies, except for
considerations of the settings to which evaluations applied
and the generalisability of the results to other decision-
making contexts. In the short-term, UKR was generally
associated with better health outcomes and lower costs than
TKR. Initial cost savings associated with UKR seem to
persist over patients’ lifetimes even after accounting for
higher rates of revision. For older patients, initial health
improvements also appear to be maintained, making UKR
the dominant treatment choice. However, for younger
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patients findings for health outcomes and overall cost
effectiveness are mixed, with the difference in health out-
comes depending on the lifetime risk of revision and
patient outcomes following revision.
Conclusions UKR appears to be less costly than TKR. For
older patients, UKR is also expected to lead to better health
outcomes,making it the dominant choice; however, for younger
patients health outcomes are more uncertain. Future research
should better account for baseline differences in patient char-
acteristics and consider how the relative value ofUKRandTKR
varies depending on patient and surgical factors.
Key Points for Decision Makers
Twelve economic evaluations comparing
unicompartmental knee replacement (UKR) with
total knee replacement (TKR) were identified and
analysed.
Model-based analysis best captured the different
factors relevant to the choice between UKR and
TKR. Studies were limited by either small sample
sizes or not accounting for baseline differences in
patient characteristics.
UKR appears to offer a less costly alternative to
TKR, and also seems to lead to better health
outcomes for older patients. Uncertainty surrounds
the difference in health outcomes for younger
patients, which depends on a patient’s lifetime risk
of revision, and health outcomes following a
revision.
1 Introduction
For patients with end-stage osteoarthritis (OA) of the knee,
total knee replacement (TKR) provides a highly effective
treatment strategy associated with significant improve-
ments in pain, function and quality of life [1, 2]. When
compared with nonsurgical treatments, TKR has been
found to be highly cost effective [3, 4]. However, for those
patients with OA predominantly in only one compartment
of the knee, unicompartmental knee replacement (UKR)
offers an alternative approach, where only the diseased
cartilage in an isolated part of the joint is replaced [5].
The choice between UKR and TKR is not clear-cut.
While UKR is associated with a significantly reduced risk
of postoperative complications and mortality as well as
better functional and general health outcomes after
6 months, [6, 7] UKR is also associated with a higher rate
of implant revision than TKR [6]. Although a primary
UKR can be expected to be cheaper than a TKR, given a
shorter hospital stay, the costs associated with revisions
and any other differences in future healthcare utilisation
could outweigh any short-term cost saving.
An economic evaluation can provide a means of
informing the choice between UKR and TKR by providing
a comparative analysis of the alternative courses of action
in terms of both their costs and health outcomes [8]. For an
economic evaluation of UKR and TKR to be useful, it
needs to use appropriate methods so that its results are
valid [8]. Given that evaluations address a question rele-
vant to a place and setting, [9] decision makers also need to
be able to consider whether the results apply to their
decision-making context [8].
This review has been undertaken to identify economic
evaluations comparing UKRs and TKRs, examine the
approaches taken, assess the quality of these evaluations,
and consider what they can tell us about the relative value
for money of the procedures.
2 Methods
2.1 Eligibility Criteria
Economic evaluations including both UKR and TKR as
treatment options for primary knee arthroplasty were eli-
gible for this review. While primary UKR and TKR were
required to be specified as treatment options, studies could
also include additional treatment alternatives. No restric-
tions were imposed on the study populations.
Only full economic evaluations, in which both the costs
and health outcomes of the alternative courses of action are
estimated, [8] could be included. Any type of economic
evaluation could have been undertaken, hence while costs
were expected to be expressed in monetary terms, health
outcomes could be measured in terms of a common unit of
clinical effect (a cost-effectiveness analysis), a generic
measure of health gain (a cost-utility analysis) or in mon-
etary units (a cost-benefit analysis).
No restriction was placed on the date of publication but
studies were required to be written in English. The review
was conducted as per the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines and the review protocol was registered
prospectively with the PROSPERO database (registration
number: CRD42015026664) [10].
2.2 Study Selection
Searcheswere undertaken in January 2016 ofMEDLINEand
EMBASE, using the OVID platform, and the Centre for
242 E. Burn et al.
Reviews and Dissemination National Health Service Eco-
nomic Evaluation Database (NHS EED), which contains
critical overviews of economic evaluations. The specific
search terms used are detailed in the ‘‘Appendix’’. Two of the
authors (EB and SP) independently screened studies for
inclusion based on their titles, with only those clearly not
eligible being excluded, and then based on abstracts, with
any discrepancies resolved by a third author (RPV). Two
authors (EB and RPV) then screened the full texts of the
remaining studies against the inclusion criteria and dis-
crepancies were resolved through consensus discussion.
2.3 Analysis of Included Studies
Economic evaluations were grouped by the type of ana-
lytical frameworks used to inform decision making. A
within-study analysis uses a single study as the vehicle for
economic analysis, [11] with data collected within the
study used to estimate costs and health outcomes. A liter-
ature review study identifies and compares estimates of
health outcomes and costs from disparate research, while a
model-based analysis defines a set of mathematical rela-
tionships to characterise the range of possible prognoses
and the impact of the alternative interventions [8].
The key characteristics of the included studies are
summarised. The ages of the study populations and the
interventions considered are noted, and the time horizon of
analysis, over which costs and health outcomes where
estimated, are recorded. The measures of overall health
outcomes are detailed. The costing perspectives are also
identified, with studies considering costs from a patient,
hospital, payer, health system, government or societal
perspective, and only those costs of relevance to the given
perspective considered in an analysis.
Subsequently, findings relating to UKR and TKR are
compared. Estimates of the difference in costs and outcomes
between UKR and TKR are summarised. The incremental
cost-effectiveness ratio (ICER), given by the difference in cost
divided by the difference in health outcome, is detailed for
studies that express health outcomes in terms of quality-ad-
justed life-years (QALYs), which provide a generic measure
of health capturing both quality and quantity of life. Where
one alternative is both cost saving and health improving, it is
considered to be the dominant treatment option. In addition,
the difference in costs and QALYs associated with under-
taking UKR rather than TKR are presented on a cost-effec-
tiveness plane. For this figure, costs were transformed into
2015 Euros by first inflating costs in the original currency to
2015 prices using Consumer Price Index (CPI) indices and
then converted to Euros using official exchange rates [12].
The methodological approaches of the studies are dis-
cussed. The specification of the decision problem, in terms
of the choice of study population and treatment options, is
assessed. The way in which estimates of effectiveness were
derived are examined, with potential sources of bias
identified. Factors relevant to the choice between UKR and
TKR included in the studies are considered. In particular,
attention is paid as to whether pain, function, or quality of
life and risk of revision were assessed when summarising
health outcomes, and whether the cost of the primary
procedure and revision procedures were incorporated into
the estimates of the overall costs.
The quality of reporting for each study is assessed using
the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) checklist, which represents a set of
reporting standards for health economic studies [9]. For
each study, items on the CHEERS checklist were assessed
as having been satisfied, partially satisfied, not satisfied, or
not applicable.
3 Results
3.1 Overview of Included Studies
Twelve studies were included in the review [13–24]. A
flowchart of the screening process is provided in the Ap-
pendix, and the key characteristics of the included studies
and the decision-making factors that they considered are
detailed in Tables 1 and 2, respectively. Estimates of
changes in costs and QALYs associated with the provision
of UKR rather than TKR are presented on a cost-effec-
tiveness plane (Fig. 1).
3.2 Within-Study Analyses
Five publications used a within-study analysis as their
framework of analysis [15, 16, 19, 23, 24]. Each of these
studies was observational and compared the costs and health
outcomes of patients who received UKR or TKR. The study
populations were similar across studies and appropriate for
those receiving the alternative procedures. To be a candidate
for either UKR or TKR individuals are required to have OA
in one compartment of the knee, to have previously failed
nonsurgical treatment, and to have symptoms that had a
substantial impact on their quality of life [25]; these were
generally the characteristics of the patients described in the
studies. While four studies imposed no age restriction for
patients to be included in the study, one included only those
older than 50 years of age, [24] while another assessed only
those over 60 years of age [16].
Two studies considered multiple peri- and postoperative
health outcomes for UKR and TKR up to 3 years following
the procedures [16, 24]. Outcomes considered included
blood loss during surgery, days required for independent
ambulation, knee flexion, and knee-specific patient-
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reported outcome measures, such as the Knee Society
score. In both studies, UKRs were matched with compa-
rable TKRs. In one study, 34 UKRs were matched with 34
TKRs on the basis of preoperative arthritis severity, range
of motion, age and sex [16], while in the other study, 50
UKRs were matched with 50 TKRs, but no details of the
matching mechanism were provided [24]. Both studies
found UKR to achieve better outcomes across all measures
considered. In addition, taking a hospital perspective, the
studies considered only the costs of primary procedures
[16, 24], and found UKR to have a lower cost than TKR.
Another study compared quality of life associated with
receiving UKR and TKR, measured using the Short-Form
(SF)-36 questionnaire [23]. Scores recorded preoperatively
and 6 and 24 months postoperatively were used to estimate
individual’s QALYs over the 2 years following surgery. It
was estimated that TKR would lead to a greater number of
QALYs than UKR. The discrepancy with this finding
compared with those of the previous studies that consid-
ered condition-specific measures of outcome is likely to be,
at least in part, because this study did not appear to control
for baseline differences between those receiving UKR and
TKR. Only the costs of the primary procedures were
considered in this analysis and, again, UKR was found to
be cost saving compared with TKR. With this study con-
sidering costs from a government and societal perspective,
excluding the costs of revision is likely inappropriate.
The two remaining studies assessed the risk of revision
followingUKRandTKRover10 and15 years usingdata from
national arthroplasty registers [15, 19]. One study did not
control for differences in the baseline characteristics of those
receiving UKR and TKR [15], while the other controlled for
age, gender and year of operation [19]. Both found UKR to be
associated with a greater risk of revision, however these esti-
matesvaried significantly. In one,UKRwas expected to have a
4 percentage point lower survival rate after 10 years, [19]
while in the other, UKRwas estimated to have a 20 percentage
point lower survival rate after 15 years [15]. Nonetheless, this
use of revision rates as a health outcomemay bemisleading as
revision of a UKR is more straightforward than revision of a
TKR. As a result, UKRs are between four and six times more
likely to be revised than a TKR, with the same functional
outcome [26]. Both studies incorporated the cost of revision
when estimating the costs of the alternative procedures.While
the study that estimated a smaller difference in risk of revision
found UKR to be cost saving compared with TKR, [19] the
study that estimated a greater differential in revision rates
found the costs of revisions to outweigh any initial savings
associated with UKR [15].
The analyses were generally well-reported, with most
items on the CHEERS checklist either partially or fully
satisfied (see Sect. 6). The interventions being compared
and the studies on which they were based were generallyT
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well reported, with the outcomes and costs described.
However, no study discussed why the analysis used was
sufficient to inform an economic evaluation of UKR and
TKR. In addition, studies did not fully describe the setting
to which the study applied, or discuss the generalisability
of their findings.
3.3 Literature Review Study
One study was informed by a literature review from which
estimates of health outcomes and costs were identified and
compared [17]. Five alternative treatments were consid-
ered, with the KineSpring implant system (Moximed, Inc.,
Hayward, CA, USA), an extra-articular device designed to
reduce the load on the knee joint [17], compared against
UKR, TKR, high tibial osteotomy (HTO) and conservative
nonsurgical treatment. The patient population to which the
analysis applied was not described in detail. Nonetheless,
the comparison of these alternative courses of action in this
study is likely inappropriate. For example, candidates for
UKR and TKR would be expected to have received and
failed nonsurgical treatments [27]. Consequently, compar-
ing the outcomes of these treatments is unlikely to be
informative as it does not reflect the choice faced in reality.
In this study, UKR and TKR were grouped together as
surgical procedures. It was assumed that both procedures
Table 2 Decision-making factors considered
Author Pain, function, or overall
quality of life
Risk of revision Cost of primary
procedures
Cost of revisions
Within-study analysis
Koskinen et al. [15] 8 4 4 4
Manzotti et al. [16] 4 8 4 8
Robertsson et al. [19] 8 4 4 4
Xie et al. [23] 4 8 4 8
Yang et al. [24] 4 8 4 8
Literature review
Marcacci et al. [17] 4 8 4 8
Decision model
Ghomrawi et al. [13] 4 4 4 4
Konopka et al. [14] 4 4 4 4
Peersman et al. [18] 4 4 4 4
Slover et al. [20] 4 4 4 4
SooHoo et al. [21] 4 4 4 4
Willis-Owen et al. [22] 4 4 4 4
Fig. 1 Cost-effectiveness plane
with study findings. Only those
studies that used QALYs as a
health outcome are included.
The horizontal axis represents
the difference in expected
QALYs following UKR and
TKR (D QALYs = UKR
QALYs-TKR QALYs); the
vertical axis represents the
difference in expected costs (D
Costs = UKR cost–TKR cost).
Study author and age group
considered are in parentheses
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would lead to the same health outcomes, in terms of
QALYs. The effect of revisions on health outcomes was
not considered. With only the costs of the primary proce-
dures considered in this analysis, as with similar within-
study analyses, UKR was estimated to be cost saving
compared with TKR.
This study mostly partially satisfied items on the
CHEERs checklist (see Sect. 6). The alternative treatments
considered were well-described; however, the rationale for
comparing them was not discussed. In addition, while the
studies included in the analysis were reported, the process
by which they were identified was not described in detail.
3.4 Model-Based Analyses
Six studies used decision-analytic models as the framework
for analysis [13, 14, 18, 20–22]. Five of the studies com-
pared UKR with TKR, [13, 18, 20–22], while one study
also included HTO as a further treatment option [14].
While two studies did not specify any age restriction
[21, 22], one study considered only those aged between 50
and 60 years [14], and another was based on those aged
78 years [20]. The remaining two studies estimated costs
and health outcomes for a number of subgroups based on
age [13, 18]. All of these model-based analyses incorpo-
rated each of the key decision-making factors relevant to
the choice between UKR and TKR (see Table 2).
Two studies used decision trees [21, 22], inwhich branches
represent possible future treatment pathways. Neither study
imposed any age restriction on the study populations that they
considered. In one study, a decision tree was only used to
estimate costs; with the costs of revisions in the year after
surgery incorporated, UKR was found to be cost saving
compared with TKR. Meanwhile, health outcomes were
measured postoperatively using the Total KneeQuestionnaire
(TKQ), with 20 UKRsmatched with 20 TKRs on age and sex
[22]. In line with the matched within-study analyses, UKR
was found to lead tobetter postoperative scores thanTKR.The
other study used a decision tree to estimate costs and health
outcomes, in terms ofQALYs, over the remaining lifetimes of
patients. As time is not explicitlymodelled in decision trees, it
was assumed that implant failure would occur for all patients
12 years following a UKR and 15 years following a TKR
[21]. This is likely a significant oversimplification, with the
risk of revision continuous over time and a proportion of
patients who are likely to never require a revision. UKR was
estimated to lead to a greater number of QALYs than TKR
[21]. In addition, with all patients expected to require a revi-
sion, UKR was also expected to be marginally more costly
than TKR [21]. UKR was expected to be cost effective, with
the estimated health gain justifying the additional cost.
The four remaining model-based analyses were each
informed by state-based Markov models [13, 14, 18, 20],
which do allow time to be explicitly modelled. Across all
of the Markov models, as time progresses patients could
remain either unrevised or have a revision. Costs and
health outcomes, in terms of QALYs, are estimated over
the remaining lifetimes of patients. Two studies allowed for
one revision following UKR and TKR [13, 20], one
allowed for up to two revisions following both procedures
[18], and no limit was placed on the number of revisions in
another study [14]. In all cases, UKR was expected to be
cost saving [13, 14, 18, 20]. Where health outcomes for
patients aged 65 years and over were estimated
[13, 18, 20], UKR was also expected to lead to better health
outcomes than TKR, making it the dominant treatment
option. However, findings for health outcomes and, in turn,
cost effectiveness were mixed for younger patients. While,
in one study, UKR was expected to lead to a gain in
QALYs compared with TKR for those under 65 years of
age [18], in another study TKR was expected to lead to
better health outcomes for those between 50 and 60 years
of age [14], while another study estimated that TKR would
lead to better health outcomes for patients aged 45 and
55 years [13]. The contrasting estimates appear to be dri-
ven by both differences in estimates for the risk of revision
and, in particular, the expected effect of revision on quality
of life. While the study that found UKR to be health
improving assumed that a revision of UKR would lead to
quality of life equivalent to that following a primary TKR
[13], the other studies expected that quality of life fol-
lowing revision of a UKR would either be equivalent to
that following revision of a TKR [13] or between that of a
primary TKR and revision of a TKR [14].
Each of the models required estimates for risk of revi-
sion following UKR and TKR. National arthroplasty reg-
istries were used in four of the studies [13, 18, 20, 22]. In
each of these it appears that the rates of revision for those
receiving UKR and TKR were compared, with no adjust-
ment made for differences in baseline characteristics. In the
two other studies, estimates were derived by a literature
review [14, 21].
The items on the CHEERS checklist were mostly either
partially or fully satisfied. The model structures were typi-
cally described in detail, but the way in which model inputs
were estimated was generally not fully explained. Mean-
while, although costs were reported in detail, the approaches
used to estimate costs, in particular when provided by hos-
pital administrators, were not fully described.
4 Discussion
A large proportion of individuals who require knee
replacement are suitable for either TKR or UKR. Sub-
stantial uncertainty exists around the identification of
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patients for whom UKR or TKR is most appropriate, and
significant variation has been observed in treatment choice
[28, 29]. While both operations have been practiced for
over 30 years, controversy remains over which is the most
suitable intervention. UKR is associated with lower rates of
early complications, morbidity and mortality, and superior
patient-reported outcomes, but TKR is associated with a
significantly lower risk of revision [6]. Economic evalua-
tions provide a method of reducing any unwarranted vari-
ation in surgical choice by providing a systematic
consideration of both the costs and health outcomes asso-
ciated with each procedure.
This review identified 12 economic evaluations that
have compared the costs and health outcomes of TKR and
UKR. Five within-study analyses and one study based on a
literature review provide a partial consideration of the costs
and health outcomes associated with the procedures, with
their focus generally either on perioperative and early
postoperative outcomes or long-term revision rates. Six
decision-analytic models provided a broader consideration
of health outcomes and costs, incorporating each of the key
factors for decision making. In particular, four studies that
used state-based Markov models were able to consider
costs and health outcomes over the remaining lifetimes of
patients following UKR and TKR.
The studies included in this review differed in time
horizons of analysis, study design, outcome measures and
costing perspectives. While methodological approaches
varied, studies generally had either limited follow-up, did
not fully account for baseline differences in patient char-
acteristics, or were informed by on previous research that
did not. The quality of reporting was generally adequate
across the included studies, except for considerations of the
settings to which evaluations applied and the generalis-
ability of the results to other decision-making contexts.
This makes it difficult for decision makers to know whether
results apply to their setting.
In the short-term, based on the economic evaluations
considered in this study, UKR appears to be associated
with better peri- and postoperative outcomes than TKR.
Better early outcomes for UKR have also been observed
for routine practice in the UK [6, 7], and are even more
pronounced for UKRs performed by high-usage and high-
volume surgeons [30]. Moreover, as would be expected
given a lower length of stay, UKR is also estimated to offer
an immediate cost saving compared with TKR.
This initial cost saving associated with UKR seems to be
maintained over patients’ lifetimes, even after accounting
for higher risk of revision. For older patients, initial health
improvements also appear to be maintained, even after
taking into account the higher risk of revision associated
with UKR. However, for younger patients with a greater
lifetime risk of revision, findings are mixed for health
outcomes and the cost effectiveness of the procedures.
Differences in both the estimates of revision risk and the
consequences associated with revisions appear to drive this
uncertainty. In particular, assumptions around quality of
life following revision of a UKR appear to be key.
Research findings are mixed as to how revision of a UKR
compares with that of a primary TKR [31–33]. Additional
research is required to better understand patients’ lifetime
risk of revision and the consequences of revisions.
As well as age, a number of other patient characteristics
have been found to be associated with differences in out-
comes following knee replacement, such as sex, weight,
and severity of symptoms [27, 34]. Surgical factors such as
surgeon grade, their caseload, and the number of cases
performed by the unit per year have also been found to be
associated with implant survival [34, 35]. Differences in
factors such as these could also influence the relative merits
of the procedures, but none of the studies identified here
considered how the cost effectiveness of UKR and TKR
varies based on any factor other than age.
Further research is required to establish the cost effec-
tiveness of UKR and TKR, and how this varies depending
on patient and surgical factors. National registries, in par-
ticular, provide a rich source of information, capturing real-
world outcomes with relatively long-term follow-up, which
are of critical importance for these procedures. If based on
such data, studies should utilise methods for addressing
potential bias, such as regression analysis or matching
estimators, to better estimate treatment effects [36]. In
addition to the numerous sources of observational data, a
large randomised controlled trial comparing UKR and
TKR is currently underway [37]. While this study will
provide valuable insight into the procedures by ascertain-
ing more comprehensively their costs and health outcomes,
data from observational studies will also be needed to
better understand the long-term effects of the procedures.
4.1 Limitations of this Review
A systematic approach was taken to identify studies that
have considered the costs and health outcomes associated
with UKR and TKR; however, there does remain the
possibility that relevant studies were not identified and
included in the study. While MEDLINE, EMBASE and
NHS EED were searched, searches of additional databases,
such as the Health Economic Evaluations Database
(HEED) may have returned more results. The search filter
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used was designed specifically for this study and has not
previously been validated. In addition, while the terms used
were chosen to find appropriate results from both data-
bases, searching MEDLINE and EMBASE together using
the OVID platform may have led to missing studies, given
the distinct characteristics of these databases.
The descriptions of the included studies provide an
objective overview of the economic evaluations that have
been undertaken of UKR and TKR and their findings but
the analysis of the methods used and quality of reporting is
necessarily subjective. While an established checklist was
used to consider the quality of reporting, categorising
studies as satisfying, partially satisfying, or not satisfying
particular items was necessarily based on the judgement of
the authors of this study.
As well as comparing the approaches taken, the key
findings of the studies have also been compared. Any
such comparison should be treated with caution due to
methodological limitations of the studies and the wide
range of factors that limit the generalisability of results
across economic evaluations [38]. In particular, cost
estimates can vary across studies due to differences in
costing perspectives of the studies and in health systems.
In addition, converting costs from one currency to
another adds further uncertainty [12]. However, a com-
parison of findings was still felt to be merited so as to
provide a broad summary of the consistency in research
findings and to provide an indication of the effect of
differences in methodological approaches on results.
Identifying such sources of variation across studies can
help individual decision makers determine which studies
best apply to their particular settings, and can guide
future research [39].
5 Conclusions
The economic evaluations of UKR and TKR that have been
undertaken vary, with differences in study populations and
methods of analysis. In the short-term, UKR appears to be
both health improving and cost saving compared with
TKR. This initial cost saving associated with UKR seems
to persist, even after accounting for higher rates of revision
over patients’ lifetimes. For older patients, UKR can also
be expected to lead to better overall health outcomes,
making it the dominant treatment choice. However, for
younger patients, findings are mixed, with differences in
estimates of the risk of revision and outcomes following
revision leading to substantial differences in estimates of
overall health outcomes.
To estimate all the costs and health outcomes associated
with the choice between UKR and TKR, future research
should incorporate long-term time horizons and estimates
of effectiveness adjusted for baseline differences in patient
characteristics. Further economic evaluations are required
to better understand how the relative value of the proce-
dures varies depending on patient and surgical factors.
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Appendix
Search Terms
Search terms for Medline and Embase via Ovid SP
1. Exp Knee Joint/
2. Knee/
3. Knee.tw.
4. Arthroplasty, Replacement, Knee/
5. Knee Prosthesis/
6. (Knee arthroplast$ or knee replacement or knee
prosthes$).tw.
7. (Uka or unicompartmental knee arthroplast$).tw.
8. Unicompartmental.tw.
9. Economics/
10. Exp ‘‘costs and cost analysis’’/
11. Exp economics, hospital/
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12. Economics, Medical/
13. Economics, Nursing/
14. Economics, Pharmaceutical/
15. (Economic$ or cost or costs or costly or costing or
price or prices or pricing or
pharmacoeconomic$).ti,ab.
16. (Expenditure$ not energy).ti,ab.
17. Value for money.ti,ab.
18. Budget$.ti,ab.
19. 1 or 2 or 3
20. 4 or 5 or 6 or 7 or 8
21. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
22. 19 and 20 and 21
NHS EED, via The Cochrane Library
1. MeSH descriptor: [Arthroplasty, Replacement, Knee]
explode all trees
2. MeSH descriptor: [Osteoarthritis, Knee] explode all
trees
3. MeSH descriptor: [Knee Joint] explode all trees
4. Knee/
5. Knee prosthesis
6. Knee arthroplasty
7. Knee replacement
8. Uka
9. Unicompartmental
10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
Screening Results
250 E. Burn et al.
S
at
is
fa
ct
io
n
o
f
th
e
C
H
E
E
R
S
ch
ec
k
li
st
W
it
h
in
-s
tu
d
y
an
al
y
si
s
L
it
er
at
u
re
re
v
ie
w
D
ec
is
io
n
m
o
d
el
K
o
sk
in
en
et
al
.
[1
4
]
M
an
zo
tt
i
et
al
.
[1
5
]
R
o
b
er
ts
so
n
et
al
.
[1
8
]
W
il
li
s-
O
w
en
et
al
.[
2
1
]
X
ie
et
al
.
[2
2
]
Y
an
g
et
al
.
[2
3
]
M
ar
ca
cc
i
et
al
.
[1
6
]
G
h
o
m
ra
w
i
et
al
.
[1
2
]
K
o
n
o
p
k
a
et
al
.
[1
3
]
P
ee
rs
m
an
et
al
.
[1
7
]
S
lo
v
er
et
al
.
[1
9
]
S
o
o
H
o
o
et
al
.
[2
0
]
T
it
le
?
±
±
?
?
±
±
?
±
?
?
?
A
b
st
ra
ct
±
±
±
±
±
±
±
±
±
?
±
±
B
ac
k
g
ro
u
n
d
an
d
o
b
je
ct
iv
es
±
±
±
±
±
±
?
?
±
?
?
±
T
ar
g
et
p
o
p
u
la
ti
o
n
an
d
su
b
g
ro
u
p
s
±
?
±
±
?
?
±
±
?
±
?
±
S
et
ti
n
g
an
d
lo
ca
ti
o
n
±
-
±
-
-
-
±
-
-
±
-
-
S
tu
d
y
p
er
sp
ec
ti
v
e
-
-
-
?
?
-
?
?
±
?
-
?
C
o
m
p
ar
at
o
rs
±
?
?
?
?
?
?
±
?
?
?
?
T
im
e
h
o
ri
zo
n
±
±
-
-
±
±
±
?
±
?
?
?
D
is
co
u
n
t
ra
te
-
-
-
-
?
-
-
?
±
?
?
?
C
h
o
ic
e
o
f
h
ea
lt
h
o
u
tc
o
m
es
±
±
±
±
±
±
±
±
?
±
±
±
M
ea
su
re
m
en
t
o
f
ef
fe
ct
iv
en
es
s
±
±
±
±
±
±
±
±
±
±
±
±
M
ea
su
re
m
en
t
an
d
v
al
u
at
io
n
o
f
p
re
fe
re
n
ce
-b
as
ed
o
u
tc
o
m
es
N
A
N
A
N
A
N
A
?
N
A
±
?
±
±
?
±
E
st
im
at
in
g
re
so
u
rc
es
an
d
co
st
s
±
±
?
±
?
-
±
±
?
±
?
?
C
u
rr
en
cy
,
p
ri
ce
d
at
e,
co
n
v
er
si
o
n
?
±
?
±
?
±
±
?
?
?
?
?
C
h
o
ic
e
o
f
m
o
d
el
N
A
N
A
N
A
±
N
A
N
A
N
A
±
?
±
±
±
M
o
d
el
as
su
m
p
ti
o
n
s
N
A
N
A
N
A
±
N
A
N
A
N
A
?
?
?
?
±
A
n
al
y
ti
c
m
et
h
o
d
s
±
±
±
±
?
±
±
?
?
±
±
±
S
tu
d
y
p
ar
am
et
er
s
±
?
?
±
?
?
±
±
?
±
±
±
In
cr
em
en
ta
l
co
st
s
an
d
o
u
tc
o
m
es
?
±
?
?
?
±
±
?
?
±
?
±
C
h
ar
ac
te
ri
si
n
g
u
n
ce
rt
ai
n
ty
-
±
±
±
±
-
-
±
?
?
?
±
C
h
ar
ac
te
ri
si
n
g
h
et
er
o
g
en
ei
ty
-
N
A
-
-
-
-
-
?
N
A
?
N
A
N
A
D
is
cu
ss
io
n
±
±
±
±
±
±
±
±
±
±
±
±
S
o
u
rc
e
o
f
fu
n
d
in
g
-
-
±
-
-
-
±
?
?
±
±
?
C
o
n
fl
ic
ts
o
f
in
te
re
st
?
-
-
?
-
-
-
?
?
?
?
-
C
H
E
E
R
S
C
o
n
so
li
d
at
ed
H
ea
lt
h
E
co
n
o
m
ic
E
v
al
u
at
io
n
R
ep
o
rt
in
g
S
ta
n
d
ar
d
s,
N
A
n
o
t
ap
p
li
ca
b
le
,
?
sa
ti
sfi
ed
,
±
p
ar
ti
al
ly
sa
ti
sfi
ed
,
-
n
o
t
sa
ti
sfi
ed
Choosing Between Unicompartmental and Total Knee Replacement 251
References
1. Ethgen O, Bruye`re O, Richy F, Dardennes C, Reginster J-Y.
Health-related quality of life in total hip and total knee arthro-
plasty. J Bone Jt Surg Am. 2004;86(5):963–74.
2. Kane RL, Saleh KJ, Wilt TJ, Bershadsky B. The functional
outcomes of total knee arthroplasty. J Bone Jt Surg.
2005;87(8):1719–24.
3. Daigle ME, Weinstein AM, Katz JN, Losina E. The cost-effec-
tiveness of total joint arthroplasty: a systematic review of pub-
lished literature. Best Pract Res Clin Rheumatol.
2012;26(5):649–58.
4. Nwachukwu BU, Bozic KJ, Schairer WW, Bernstein JL, Jevsevar
DS, Marx RG, et al. Current status of cost utility analyses in total
joint arthroplasty: a systematic review. Clin Orthop Relat Res.
2015;473(5):1815–27.
5. Ashraf ST, Ackroyd CE, Newman JH. Compartmental knee
arthroplasty. Curr Orthop. 2003;17(2):134–43.
6. Liddle AD, Judge A, Pandit H, Murray DW. Adverse outcomes
after total and unicompartmental knee replacement in 101 330
matched patients: a study of data from the National Joint Registry
for England and Wales. Lancet. 2014;384(9952):1437–45.
7. Liddle AD, Pandit H, Judge A, Murray DW. Patient-reported
outcomes after total and unicompartmental knee arthroplasty: a
study of 14,076 matched patients from the National Joint Registry
for England and Wales. Bone Jt J. 2015;97-B(6):793–801.
8. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance
GW, Drummond MF, et al. Methods for the Economic Evaluation
of Health Care Programmes. Oxford: Oxford University Press;
2015.
9. Husereau D, Drummond M, Petrou S, Carswell C, Moher D,
Greenberg D, et al. Consolidated Health Economic Evaluation
Reporting Standards (CHEERS)–explanation and elaboration: a
report of the ISPOR Health Economic Evaluation Publication
Guidelines Good Reporting Practices Task Force. Value Health.
2013;16(2):231–50.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, Group Prisma.
Preferred reporting items for systematic reviews and meta-anal-
yses: the PRISMA statement. BMJ. 2009;339:b2535.
11. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither
trial-based economic evaluation for health care decision making?
Health Econ. 2006;15(7):677–87.
12. Gosden TB, Torgerson DJ. Converting international cost effec-
tiveness data to UK prices. BMJ. 2002;325(7358):275–6.
13. Ghomrawi HM, Eggman AA, Pearle AD. Effect of age on cost-
effectiveness of unicompartmental knee arthroplasty compared
with total knee arthroplasty in the US. J Bone Jt Surg Am.
2015;97(5):396–402.
14. Konopka JF, Gomoll AH, Thornhill TS, Katz JN, Losina E. The
cost-effectiveness of surgical treatment of medial unicompart-
mental knee osteoarthritis in younger patients: a computer model-
based evaluation. J Bone Jt Surg Am. 2015;97(10):807–17.
15. Koskinen E, Eskelinen A, Paavolainen P, Pulkkinen P, Remes V.
Comparison of survival and cost-effectiveness between uni-
condylar arthroplasty and total knee arthroplasty in patients with
primary osteoarthritis: a follow-up study of 50,493 knee
replacements from the Finnish Arthroplasty Register. Acta
Orthop. 2008;79(4):499–507.
16. Manzotti A, Confalonieri N, Pullen C. Unicompartmental versus
computer-assisted total knee replacement for medial compart-
ment knee arthritis: a matched paired study. Int Orthop.
2007;31(3):315–9.
17. Marcacci M, Zaffagnini S, Li CS, Bhandari M. Cost-effectiveness
and Economic Impact of the KineSpring Knee Implant System
in the Treatment of Knee Osteoarthritis in Italy. J Long-Term Eff
Med Implants. 2013;23(2):211-222.
18. Peersman G, Jak W, Vandenlangenbergh T, Jans C, Cartier P,
Fennema P. Cost-effectiveness of unicondylar versus total knee
arthroplasty: a Markov model analysis. Knee. 2014;21:S37–42.
19. Robertsson O, Borgquist L, Knutson K, Lewold S, Lidgren L.
Use of unicompartmental instead of tricompart-mental prostheses
for unicompartmental arthrosis in the knee is a cost-effective
alternative: 15,437 primary tricompartmental prostheses were
compared with 10,624 primary medial or lateral unicompart-
mental prostheses. Acta Orthopaed. 1999;70(2):170–5.
20. Slover J, Espehaug B, Havelin LI, Engesaeter LB, Furnes O,
Tomek I, et al. Cost-effectiveness of unicompartmental and total
knee arthroplasty in elderly low-demand patients. A Markov
decision analysis. J Bone Jt Surg Am. 2006;88(11):2348–55.
21. Soohoo NF, Sharifi H, Kominski G, Lieberman JR. Cost-effec-
tiveness analysis of unicompartmental knee arthroplasty as an
alternative to total knee arthroplasty for unicompartmental
osteoarthritis. J Bone Jt Surg Am. 2006;88(9):1975–82.
22. Willis-Owen CA, Brust K, Alsop H, Miraldo M, Cobb JP. Uni-
condylar knee arthroplasty in the UK National Health Service: an
analysis of candidacy, outcome and cost efficacy. Knee.
2009;16(6):473–8.
23. Xie F, Lo NN, Tarride JE, O’Reilly D, Goeree R, Lee HP. Total
or partial knee replacement? Cost-utility analysis in patients with
knee osteoarthritis based on a 2-year observational study. Eur J
Health Econ. 2010;11(1):27–34.
24. Yang KY, Wang MC, Yeo SJ, Lo NN. Minimally invasive uni-
condylar versus total condylar knee arthroplasty: early results of a
matched-pair comparison. Singap Med J. 2003;44:559–62.
25. National Institute for Health and Care Excellence. Osteoarthritis:
care and management. NICE guidelines [CG177]. London:
National Institutes for Health and Care Excellence; 2014.
26. Goodfellow JW, O’Connor JJ, Murray DW. A critique of revision
rate as an outcome measure: re-interpretation of knee joint reg-
istry data. J Bone Jt Surg Br. 2010;92(12):1628–31.
27. Carr AJ, Robertsson O, Graves S, Price AJ, Arden NK, Judge A,
et al. Knee replacement. Lancet. 2012;379(9823):1331–40.
28. Beard DJ, Holt MD, Mullins MM, Malek S, Massa E, Price AJ.
Decision making for knee replacement: variation in treatment
choice for late stage medial compartment osteoarthritis. Knee.
2012;19(6):886–9.
29. Williams DP, Blakey CM, Hadfield SG, Murray DW, Price AJ,
Field RE. Long-term trends in the Oxford knee score following
total knee replacement. Bone Jt J. 2013;95-B(1):45–51.
30. Burn E, Sanchez-Santos MT, Pandit HG, Hamilton TW, Liddle
AD, Murray DW, et al. Ten-year patient-reported outcomes fol-
lowing total and minimally invasive unicompartmental knee
arthroplasty: a propensity score-matched cohort analysis. Knee
Surg Sports Traumatol Arthrosc. Epub 29 Dec 2016.
31. Jones WH, Chan W, Harrison T, Smith TO, Masonda P, Walton
NP. Revision of medial Oxford unicompartmental knee replace-
ment to a total knee replacement: similar to a primary? Knee.
2012;19(4):339–43.
32. Martin JG, Wallace DA, Woods DA, Carr AJ, Murray DW.
Revision of unicondylar knee replacements to total knee
replacement. Knee. 1995;2(2):121–5.
33. Saldanha KA, Keys GW, Svard UC, White SH, Rao C. Revision
of Oxford medial unicompartmental knee arthroplasty to total
knee arthroplasty—results of a multicentre study. Knee.
2007;14(4):275–9.
34. Liddle AD, Judge A, Pandit H, Murray DW. Determinants of
revision and functional outcome following unicompartmental
knee replacement. Osteoarthr Cartil. 2014;22(9):1241–50.
252 E. Burn et al.
35. Liddle AD, Pandit H, Judge A, Murray DW. Effect of surgical
caseload on revision rate following unicompartmental and total
knee replacement. J Bone Jt Surg Am. 2016;98(1):1–8.
36. Jones AM, Rice N. Econometric evaluation of health policies.
Oxford: Oxford University Press; 2012.
37. Beard D, Price A, Cook J, Fitzpatrick R, Carr A, Campbell M,
et al. Total or Partial Knee Arthroplasty Trial-TOPKAT: study
protocol for a randomised controlled trial. Trials. 2013;14:292.
38. Anderson R. Systematic reviews of economic evaluations: utility
or futility? Health Econ. 2010;19(3):350–64.
39. Pignone M, Saha S, Hoerger T, Lohr KN, Teutsch S, Mandelblatt
J. Challenges in systematic reviews of economic analyses. Ann
Intern Med. 2005;142((12_Part_2)):1073–9.
Choosing Between Unicompartmental and Total Knee Replacement 253
